Equities Analysts Offer Predictions for PBYI FY2024 Earnings

Puma Biotechnology, Inc. (NASDAQ:PBYI) – Equities research analysts at Zacks Research cut their FY2024 EPS estimates for shares of Puma Biotechnology in a research report issued to clients and investors on Thursday, January 9th. Zacks Research analyst R. Department now expects that the biopharmaceutical company will post earnings of $0.31 per share for the year, down from their previous estimate of $0.32. The consensus estimate for Puma Biotechnology’s current full-year earnings is $0.31 per share. Zacks Research also issued estimates for Puma Biotechnology’s Q1 2025 earnings at $0.03 EPS, Q4 2025 earnings at $0.13 EPS, Q1 2026 earnings at $0.01 EPS, Q3 2026 earnings at $0.12 EPS, Q4 2026 earnings at $0.07 EPS and FY2026 earnings at $0.25 EPS.

A number of other equities research analysts also recently issued reports on PBYI. HC Wainwright reissued a “buy” rating and set a $7.00 price target on shares of Puma Biotechnology in a research report on Monday, December 23rd. StockNews.com lowered shares of Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a report on Friday, December 6th.

Puma Biotechnology Price Performance

Puma Biotechnology stock opened at $3.31 on Monday. Puma Biotechnology has a 1 year low of $2.22 and a 1 year high of $7.73. The firm has a 50 day moving average price of $3.06 and a 200 day moving average price of $2.99. The company has a market cap of $162.48 million, a price-to-earnings ratio of 6.90 and a beta of 1.10. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.40 and a current ratio of 1.42.

Puma Biotechnology (NASDAQ:PBYI) last issued its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported $0.41 earnings per share for the quarter, topping analysts’ consensus estimates of $0.31 by $0.10. Puma Biotechnology had a return on equity of 41.60% and a net margin of 9.56%. The company had revenue of $80.50 million for the quarter, compared to analyst estimates of $71.32 million. During the same quarter in the prior year, the company posted $0.12 EPS.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in PBYI. Los Angeles Capital Management LLC bought a new stake in Puma Biotechnology in the third quarter worth about $627,000. FMR LLC boosted its stake in Puma Biotechnology by 27.1% in the 3rd quarter. FMR LLC now owns 118,265 shares of the biopharmaceutical company’s stock worth $302,000 after purchasing an additional 25,183 shares during the period. Barclays PLC grew its holdings in shares of Puma Biotechnology by 146.5% during the third quarter. Barclays PLC now owns 78,021 shares of the biopharmaceutical company’s stock valued at $199,000 after buying an additional 46,370 shares in the last quarter. Franklin Resources Inc. purchased a new position in Puma Biotechnology during the 3rd quarter valued at about $41,000. Finally, Affinity Asset Advisors LLC purchased a new position in Puma Biotechnology during the second quarter valued at approximately $815,000. 61.29% of the stock is currently owned by institutional investors.

Insider Transactions at Puma Biotechnology

In other Puma Biotechnology news, CEO Alan H. Auerbach sold 33,841 shares of the firm’s stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $3.15, for a total value of $106,599.15. Following the sale, the chief executive officer now directly owns 7,029,674 shares in the company, valued at approximately $22,143,473.10. This trade represents a 0.48 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Jeffrey Jerome Ludwig sold 9,437 shares of the stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $3.15, for a total transaction of $29,726.55. Following the completion of the sale, the insider now directly owns 108,951 shares in the company, valued at approximately $343,195.65. This trade represents a 7.97 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 23.70% of the company’s stock.

About Puma Biotechnology

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.